Evidence map›Paper›PMID 27274624›Full record

ArticleJournal of proteomics & bioinformatics2016

Proteomic Findings in Melanoma.

Deepanwita Sengupta, Alan J Tackett

Abstract read
In one paragraph

Article in Journal of proteomics & bioinformatics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Deepanwita SenguptaDepartment of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, 4301 West Markham Street, Little Rock, Arkansas 72205, USA.
Alan J TackettDepartment of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, 4301 West Markham Street, Little Rock, Arkansas 72205, USA; Department of Pathology, University of Arkansas for Medical Sciences, 4301 West Markham Street, Little Rock, Arkansas 72205, USA.

Funding

Understanding Hesitant AdoptersP20GM103429 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI Lawrence E Cornett, JERRY WARE · 2012 to 2026
$60.9M
Study of the Cell-specific Inflammasome Responses During Defense Against Gram-negative BacteriaP20GM103625 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI SMELTZER, MARK S · 2012 to 2021
$21.5M
Arkansas Center for Clinical and Translational ResearchUL1TR000039 · NCATS · UNIV OF ARKANSAS FOR MED SCIS · PI BECK, CORNELIA MARIE, JAMES, LAURA P · 2012 to 2014
$10.0M
Using ChAP-MS to Study Macromolecular Chromatin Composition during TranscriptionR01GM106024 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI TACKETT, ALAN, TAVERNA, SEAN D. · 2013 to 2016
$1.2M
Orbitrap Fusion Tribrid Mass SpectrometerS10OD018445 · OD · UNIV OF ARKANSAS FOR MED SCIS · PI MACKINTOSH, SAMUEL G. · 2015 to 2015
$856k
Development of MassSQUIRM to Quantitatively Measure Lysine MethylationR33CA173264 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI TACKETT, ALAN · 2013 to 2015
$430k
NCATS NIH HHS UL1 TR000039NCI NIH HHS R33 CA173264NIGMS NIH HHS P20 GM103429NIGMS NIH HHS P20 GM103625NIGMS NIH HHS R01 GM106024NIH HHS S10 OD018445
6 · The paper itself

Abstract

Although the emergence of proteomics as an independent branch of science is fairly recent, within a short period of time it has contributed substantially in various disciplines. The tool of mass spectrometry has become indispensable in the analysis of complex biological samples. Clinical applications of proteomics include detection of predictive and diagnostic markers, understanding mechanism of action of drugs as well as resistance mechanisms against them and assessment of therapeutic efficacy and toxicity of drugs in patients. Here, we have summarized the major contributions of proteomics towards the study of melanoma, which is a deadly variety of skin cancer with a high mortality rate.

Indexed as

BiomarkersMass spectrometryMelanomaProteomics

Identifiers

PMID27274624
PMCPMC4888906

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.